We are excited to share that Fusix Biotech was selected to compete in the semi-finals of the 9th edition of EIT Health Catapult. Each year, the competition showcases Europe’s most promising life science and healthtech start-ups to leading experts and investors. The Catapult programme has supported over 330 companies in the eight editions so far, with many closing multi-million investment rounds of euros after participating. Participants often highlight that the EIT Health Catapult flagship programme, where European partners and industry leaders assess all critical aspects of businesses, has been invaluable to start-ups.
